Literature DB >> 3447646

Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle.

D A Weimer1, W L Donegan.   

Abstract

This study was undertaken to determine if hormone receptor activity in breast cancers changes during different phases of the menstrual cycle. Estrogen (ER) and progesterone (PgR) receptors in seventy-eight primary breast carcinomas from premenopausal women were compared with the phase of the menstrual cycle at the time of biopsy. The frequency of ER positivity did not change, but PgR positivity became significantly higher after the early follicular phase. An increase in mean ER and PgR concentration was found (p less than .05) in the late luteal phase. The results indicate that tumor ER and PgR values change during the menstrual cycle, probably in response to endogenous hormonal fluctuations, and this may account for some vicissitudes in establishing hormone dependence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3447646     DOI: 10.1007/BF01805764

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  16 in total

1.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

2.  Influence of endogenous hormone levels on tumor estradiol and progesterone receptors.

Authors:  S Saez; C Chouvet
Journal:  Recent Results Cancer Res       Date:  1984

3.  Estrogen and progesterone receptors in human breast cancer with concomitant assay of plasma 17beta-estradiol, progesterone, and prolactin levels.

Authors:  R Nagai; M Kataoka; S Kobayashi; K Ishihara; N Tobioka; K Nakashima; M Naruse; K Saito; S Sakuma
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701

4.  The value of progesterone receptor assays in the management of advanced breast cancer.

Authors:  G A Degenshein; N Bloom; E Tobin
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Augmentation of progesterone receptor concentration by progesterone and estrogen treatments in the chick oviduct.

Authors:  T Ylikomi; J Isola; J Ratia; T Vähä-Tahlo; P Tuohimaa
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

6.  Relationship between primary breast tumor receptor status and patient survival.

Authors:  R W Blamey; H M Bishop; J R Blake; P J Doyle; C W Elston; J L Haybittle; R I Nicholson; K Griffiths
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

7.  Prognostic value of estrogen receptor determinations in patients with breast cancer.

Authors:  M A Rich; P Furmanski; S C Brooks
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

8.  Estrogen receptors and breast cancer: prognostic and therapeutic implications.

Authors:  P V Gapinski; W L Donegan
Journal:  Surgery       Date:  1980-09       Impact factor: 3.982

9.  Estradiol receptor in human breast cancers throughout the menstrual cycle.

Authors:  E Heise; M Görlich
Journal:  Oncology       Date:  1982       Impact factor: 2.935

10.  Variations in estrogen and progesterone receptor content in premenopausal breast cancer patients throughout the menstrual cycle.

Authors:  D Coradini; V Cappelletti; P Miodini; E Ronchi; G Scavone; G Di Fronzo
Journal:  Tumori       Date:  1984-08-31
View more
  3 in total

1.  Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas.

Authors:  R L Katz; S Patel; N Sneige; H A Fritsche; G N Hortobagyi; F C Ames; T Brooks; N G Ordonez
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

Review 2.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy.

Authors:  K Holli; J Isola; M Hakama
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.